Medrego, the leading producer of veterinary regenerative medicine solutions in Northern Europe has launched its new Stem Cell Therapy product for dogs – CaniCell.
Spending years of research & development in biotechnology solutions, and cooperating with the best veterinarians and scientists in the region, have led us to a new product launch in 2019.
Addressing the biggest health problem for dogs worldwide
CaniCell is a new age therapy that has shown tremendous effects on managing osteoarthritis and other degenerative diseases in dogs.
Almost a quarter of all dog population worldwide will suffer from arthritis at one point in their lives. Osteoarthritis is the most common form of arthritis, both in human and in dogs, and it is also a major cause of disability. It is mainly characterized by an activation of inflammatory processes at a molecular level, ultimately leading to a gradual deterioration of the cartilage.
For decades veterinarians have prescribed drugs, physical therapy, weight control and many other arthritis management options. The new age therapy CaniCell comes with many benefits over the traditional ways of treatments. It may become the “golden standard” for managing osteoarthritis in the near future, because of its simplicity.
It is time sparing, cost-effective, minimally invasive one-step procedure.
CaniCell – Healing the happiness of dog owners
There are two options for this Stem Cell Therapy. Dog owners can choose whether they want their dog to receive CaniCell Stem Cell transplantation therapy that has been prepared using tissue collected from a young and healthy donor individual, or they want to use their own dog’s tissue for product preparation and transplantation.
Both therapy options have the highest safety criteria and have been tested for any contamination and are manufactured by relevant quality standards.
“We are thrilled to see the results from our new transplantation therapy. We are healing the happiness of the dog owners with this innovation”, says business manager of Medrego, Mr. Normunds Daudiss. “Our aim is to be able to offer our clients
By offering our clients an allogeneic (donor-derived) Stem Cell transplantation therapy, Medrego has managed to become an affordable alternative to regular treatments.
Veterinarians and pet owners, all over the world, are finally able to help their four-legged friends and manage the pain caused by degenerative diseases such as arthritis and dysplasia.
Promising future for Stem Cell treatments ahead
CaniCell’s properties are highly useful for healing of soft tissue injuries, tendon and ligament tears, and muscle injuries. Studies have shown that the transplanted Stem Cells move to the inflamed or damaged tissue of the joint, suppress the inflammation, relieve pain, and cause new tissue to grow. Stem Cells can regenerate tissues such as cartilage, bone, tendon, and muscle.
Studies have shown up to 90% positive feedback from veterinarians and dog owners after the use of donor-derived Stem Cell therapy, during the period of 6
Medrego Stem Cell transplantation therapy (CaniCell) is not a medicinal product or a veterinary drug. Our Stem Cell Therapy dose contains unmodified sterile animal mesenchymal tissue cells, meant only for transplantation in a specific animal.
We are following the EMA safety guidelines to ensure the highest safety profile.